AbbVie Inc. (BKK:ABBV19)

Market Cap	11.92T
Revenue (ttm)	1.94T
Net Income (ttm)	76.25B
Shares Out	n/a
EPS (ttm)	42.89
PE Ratio	156.38
Forward PE	15.98
Dividend	0.09 (1.33%)
Ex-Dividend Date	Jan 16, 2026

Volume	134,122
Average Volume	73,973
Open	7.00
Previous Close	7.00
Day's Range	6.80 - 7.00
52-Week Range	6.80 - 8.10
Beta	n/a
RSI	36.77
Earnings Date	Feb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: ABBV19

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD